Gerresheimer AG reports that it has commenced commercial production of ClikSTAR® insulin pens for global healthcare company sanofi- aventis. The insulin pens incorporate a dosage and application function.
Gerresheimer's press release says the insulin pen was prepared in Wackersdorf, the company's Plastics Division's technology center. Its Pfreimd, Germany plant manufactures and assembles individual pen components under clean room conditions.
Insulin pens are drug delivery systems in pen format that enable diabetes sufferers to reliably administer their regular insulin doses in a virtually pain-free procedure. Diabetes treatment is gaining in significance from year to year. According to the World Health Organization (WHO) estimates, there will be around 350 million diabetes sufferers in the world by the year 2030.
“We are delighted about this sanofi-aventis production project because it involves a complex product that demonstrates our leadership in the medical plastic systems market to the pharma industry,” said Uwe Röhrhoff, Gerresheimer's CEO.
Gerresheimer's press release says the insulin pen was prepared in Wackersdorf, the company's Plastics Division's technology center. Its Pfreimd, Germany plant manufactures and assembles individual pen components under clean room conditions.
Insulin pens are drug delivery systems in pen format that enable diabetes sufferers to reliably administer their regular insulin doses in a virtually pain-free procedure. Diabetes treatment is gaining in significance from year to year. According to the World Health Organization (WHO) estimates, there will be around 350 million diabetes sufferers in the world by the year 2030.
“We are delighted about this sanofi-aventis production project because it involves a complex product that demonstrates our leadership in the medical plastic systems market to the pharma industry,” said Uwe Röhrhoff, Gerresheimer's CEO.
